Tumor Biology

, Volume 35, Issue 2, pp 923–927 | Cite as

Association of XRCC5 VNTR polymorphism with the development of chronic myeloid leukemia

  • Manjula Gorre
  • Prajitha Edathara Mohandas
  • Sailaja Kagita
  • Sandhya Annamaneni
  • Raghunadharao Digumarti
  • Vishnupriya Satti
Research Article


Double-strand breaks (DSBs) inducing agents influence the fidelity of DNA repair in both normal cells and leukemic cells, causing major genomic instability. In eukaryotic cells, non-homologous end joining pathway (NHEJ) is the major mechanism for DSB repair. Human X-ray repair cross-complementing 5 (XRCC5) gene encodes for the protein KU86, an important component of NHEJ pathway. Variable number of tandem repeats (VNTR) polymorphism (rs 6147172) in the promoter region of XRCC5 gene was shown to have effect on gene expression and was found to be associated with the development of several cancers. We analyzed VNTR polymorphism of XRCC5 gene in 461 chronic myeloid leukemia (CML) cases and 408 controls by polymerase chain reaction. Our results showed that frequency of 0R/0R genotype was significantly elevated in CML cases compared to that of controls (p = 0.05). Significant difference in the genotype distribution was observed between cases and controls (p = 0.02). The risk of CML development was found to be elevated for individuals carrying lower repeats (1R p = 0.03; 0R p = 0.007). Elevated 0R/0R genotype frequency was found to be significantly associated with early age at onset (≤30 years) and slightly elevated in chronic phase and poor hematologic response to imatinib mesylate. The influence of zero repeat on enhanced expression of XRCC5 might confer risk to error-prone repair leading to genomic instability and CML. Hence, the VNTR polymorphism in the promoter region of XRCC5 gene could serve as an important prognostic marker in CML development.





We are thankful to the Council of Scientific and Industrial Research (CSIR) and Osmania University–Department of Science and Technology (OU-DST-PURSE) program for their financial assistance.

Conflicts of interest



  1. 1.
    Faderl S, Talpaz M, Estrov Z, OBrien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Khanna KK, Jackson SP. DNA double strand breaks: signaling, repair, and the cancer connection. Nat Genet. 2001;27:247–54.PubMedCrossRefGoogle Scholar
  3. 3.
    Nicola B, Terry JG, Manyee C, Ghulam JM, Feyruz VR. Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key non homologous end-joining proteins. Cancer Res. 2003;63:1798–805.Google Scholar
  4. 4.
    Cai QQ, Plet A, Imbert J, Lafage-Pochitaloff M, Cerdan C, Blanchard JM. Chromosomal location and expression of the genes coding for Ku p70 and p80 in human cell lines and normal tissues. Cytogenet Cell Genet. 1994;65:221–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Stronati L, Gensabella G, Lamberti C, Barattini P, Frasca D, Tanzarella C, et al. Expression and DNA binding activity of the Ku heterodimer in bladder carcinoma. Cancer. 2001;92:2484–92.PubMedCrossRefGoogle Scholar
  6. 6.
    Pucci S, Mazzarelli P, Rabitti C, Giai M, Gallucci M, Flammia G, et al. Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies. Oncogene. 2001;20:739–47.PubMedCrossRefGoogle Scholar
  7. 7.
    Yang MD, Tsai CW, Chang WS, Tsou YA, Wu CN, Bau DT. Predictive role of XRCC5/XRCC6 genotypes in digestive system cancers. World J Gastrointest Oncol. 2011;3(12):175–81.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Ludwig DL, Chen F, Peterson SR, Nussenzweig A, Li GC, Chen DJ. Ku80 gene expression is Sp1-dependent and sensitive to CpG methylation within a novel cis element. Gene. 1997;199:181–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Wang S, Wang M, Yin S, Fu G, Li C, Chen R, et al. A novel variable number of tandem repeats (VNTR) polymorphism containing Sp1 binding elements in the promoter of XRCC5 is a risk factor for human bladder cancer. Mutat Res. 2008;638:26–36.PubMedCrossRefGoogle Scholar
  10. 10.
    Rajaei M, Saadat I, Saadat M. High-resolution melting analysis for detection of variable number of tandem repeats polymorphism of XRCC5. Biochem Biophys Res Commun. 2012;425:398–400.PubMedCrossRefGoogle Scholar
  11. 11.
    Rajaei M, Saadat I, Saadat I. The novel allele (3R) of the VNTR polymorphism in the XRCC5promoter region dramatically decreases the gene expression. Biochem Biophys Res Commun. 2013;430:640–1.PubMedCrossRefGoogle Scholar
  12. 12.
    Rajaei M, Saadat I, Saadat M. Introducing a novel allele for the polymorphism of variable number of tandem repeats in the promoter region of XRCC5. Biochem Biophys Res Commun. 2012;427:503–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Lahiri DK, Nurnberger Jr JI. A rapid nonenzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19(19):5444.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Wang G, Wang S, Shen Q, Yin S, Li C, Li A, et al. Polymorphisms inXRCC5, XRCC6, XRCC7 genes are involved in DNA double-strand breaks (DSBs) repair associated with the risk of acute myeloid leukemia (AML) in Chinese population. J Nanjing Med Univ. 2009;23(2):93–9.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Manjula Gorre
    • 1
  • Prajitha Edathara Mohandas
    • 2
  • Sailaja Kagita
    • 3
  • Sandhya Annamaneni
    • 4
  • Raghunadharao Digumarti
    • 5
  • Vishnupriya Satti
    • 6
  1. 1.CSIR-SRF, Department of GeneticsOsmania UniversityHyderabadIndia
  2. 2.CSIR-JRF, Department of GeneticsOsmania UniversityHyderabadIndia
  3. 3.PDF, Department of Medical OncologyNizam’s Institute of Medical SciencesHyderabadIndia
  4. 4.Indian Statistical InstituteHyderabadIndia
  5. 5.Department of Medical OncologyNizam’s Institute of Medical SciencesHyderabadIndia
  6. 6.Department of GeneticsOsmania UniversityHyderabadIndia

Personalised recommendations